



## DAVID STAKNIS, PHD

Dr. Staknis has extensive expertise investigating and evaluating markets, regulatory issues, and technologies for pharmaceutical, diagnostic, medical device and service provider clients. As the Health and Life Sciences Principal at Fuld + Company, Dr. Staknis with his team supports clients' needs in business development target identification, clinical stage R&D development landscape assessment, and best practices for commercialization strategies and tactics. He is well versed in strategic competitive simulations and scenario analysis workshops, along with traditional market monitoring.

### EXPERTISE

Prior to joining Fuld, Dr. Staknis was a Senior Analyst and Division Leader at Global Prior Art, Inc., an intellectual property search and consulting firm. In that position, he worked closely with law firms, biotechnology and pharmaceutical companies to support patent litigation and prosecution, perform freedom-to-operate searches, and create intellectual property landscapes. He has worked in a variety of fields ranging from polypeptide, nucleic acid and small molecule therapeutic agents, diagnostic systems, drug screening methods and production methods. Dr. Staknis was also a biology instructor at Northeastern University and has fourteen years of bench research experience.

### EDUCATION

Dr. Staknis holds a B.S. in biology from Syracuse University and a Ph.D. in cellular and developmental biology from Harvard University. His graduate work focused on the assembly of the mammalian spliceosome complex that performs messenger RNA splicing. His post-doctoral studies, performed at Harvard Medical School, focused on characterizing the molecular components and mechanisms of vertebrate circadian rhythms.